NCT02367638已完成1 期
A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 主要终点
- To evaluate the unsolicited adverse events during 42 days after vaccination
研究概览
简要总结
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female individuals between 20 and 55 years of age at screening test
- •In the case of female, individuals must be applicable for one of the following;
- •In the case of female of childbearing potential, any negative pregnancy test using urine hCG at screening
- •Menopausal for at least 2 years
- •Surgical sterilization (status after hysterectomy, bilateral oophorectomy, bilateral tubal ligation or the status using other contraceptive methods)
- •Monogamous relationship with vasectomized partner prior to screening visit
- •Individuals who are used acceptable contraceptive methods from 3 month prior to the subject's study entry to 1 month after vaccination (acceptable contraceptive methods; condom, diaphragm or cervical cap)
- •If male who is sexually active with the female "of childbearing potential" , the individuals who agree to use any of the acceptable contraceptive methods during this study period and agree to not donate the sperm until 1 month
- •At screening visits, individuals who are over 55 kg in man, over 50kg in woman and whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)
- •Individual who has no clinically significant abnormalities in screening test within 28 days prior to vaccination
- •Individuals who were voluntarily signed informed consent form after receiving education about this study and able to comply with the requirements for the study
排除标准
- •Individuals who received any other vaccines within 4 weeks prior to the screening visit
- •Individuals who are planning to receive the other vaccines during this study
- •Individuals who had wound, scar, tattoo, dermatological disorders or injection affecting safety evaluation
- •Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : >5 cups/day, alcohol : 210g/week, smoke : 10 /day)
- •Individuals who received any other investigational product within 90 days prior to vaccination
- •individuals who donated the whole blood within 60 days or apheresis within 30 days prior to vaccinating investigational product
- •Individuals who administered with another prescription medicine, herbal medicine within 14 days or over-the-counter drug or vitamins within 7 days before vaccination
- •Individuals with history or illness affecting immune system (1) individuals with continuously anti-viral therapy within 6 months prior to participating in this study (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia, dysgammaglobulinemia) (4) Individuals who are receiving immunosuppressive therapy (5) Individuals who have treated immunoglobulin or blood-derived products within 6 months of enrollment (6) Individuals with a family history of congenital or hereditary immunodeficiency
- •Individuals with any clinically relevant history of other disease or disorder - gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome), psychiatric or malignant tumor
- •Individuals with any febrile illness or body temperature ≥38℃ before vaccination
- •Individuals known hypersensitivity or allergy to components of investigational product (including gelatin and neomycin)
- •Individuals who are any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG, and clinical laboratory tests
- •Pregnancy or breastfeeding
- •Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
结局指标
主要结局
To evaluate the unsolicited adverse events during 42 days after vaccination
时间窗: 42 days
To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination
时间窗: 7 days
次要结局
- To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42(42 days)
- To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42(42 days)
研究者
相似试验
已完成
1 期
A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and ChildrenVaricellaNCT02965404Sinovac (Dalian) Vaccine Technology Co., Ltd.270
已完成
2 期
Efficacy and safety of live varicella vaccine in patients with diabetes mellitus associated with decreased cell-mediated immunity: a Randomized, Double-blind, Placebo-controlled Trialdiabetes mellitusJPRN-UMIN000018879Kitano hospital, The Tazuke Kofukai Medical Research Institute80
已完成
1 期
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had ChickenpoxChickenpoxHIV InfectionsNCT00001125National Institute of Allergy and Infectious Diseases (NIAID)60
已完成
2 期
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).VaricellaNCT00792623GlaxoSmithKline45
已完成
3 期
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesVaricellaNCT06314724Sinovac (Dalian) Vaccine Technology Co., Ltd.642